Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 334Carcinoma, Renal Cell 112Urinary Bladder Neoplasms 95Breast Neoplasms 55Carcinoma, Transitional Cell 52Colorectal Neoplasms 43Carcinoma, Non-Small-Cell Lung 42Melanoma 41Ovarian Neoplasms 39Kidney Neoplasms 39Neoplasms 38Neoplasm Metastasis 31Lung Neoplasms 28Sarcoma 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Pancreatic Neoplasms 24Endometrial Neoplasms 23Stomach Neoplasms 22Wilms Tumor 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Hepatocellular 19Esophageal Neoplasms 18Adenocarcinoma 18Triple Negative Breast Neoplasms 17Head and Neck Neoplasms 17Small Cell Lung Carcinoma 15Thyroid Neoplasms 14Metastatic Castration-resistant Prostate Cancer 14Neuroblastoma 13

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × Genitourinary × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡